A total of 101 preterm infants between 26 and 37 weeks' gestation who received BCG vaccination at birth were evaluated between two and four months after vaccination. Altogether 32% of these infants had no visible BCG scar. The efficacy of BCG vaccination and its protection against tuberculosis in the full term infant after birth has been shown by several studies.'-3 BCG vaccination is recommended by the World Health Organisation for control of the disease in countries with a high incidence of tuberculosis.4 This policy is not routinely applied in preterm infants who may be at greater risk of infection than term infants. To the best of our knowledge there are no data on the effectiveness of BCG vaccination in preterm infants of less than 32 weeks' gestation and similar information on preterm babies of more than 32 weeks is limited.5
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Abstract A total of 101 preterm infants between 26 and 37 weeks' gestation who received BCG vaccination at birth were evaluated between two and four months after vaccination. Altogether 32% of these infants had no visible BCG scar. All infants were then tested with tuberculin purified protein derivative (PPD) but only 70 returned for the test to be read 48-72 hours later. The test was negative in 22 (31%) and there was an induration of s,5 mm in another 26 (37%) of the infants. Of 22 infants with no BCG scar, 19 (86%) had an induration of s 5 mm. In infants with a positive BCG scar a significantly higher number had an induration of PPD >5 mm. There were no significant differences between the rate of scarring and tuberculin conversion in the infants born before or after 32 weeks' gestation. It is considered that routine BCG vaccination at birth on preterm infants is not indicated until a much larger study has been performed. The efficacy of BCG vaccination and its protection against tuberculosis in the full term infant after birth has been shown by several studies. Republic of Germany. A homogenous suspension in a concentration of 0 5 mg/ml was made and 0-1 ml given intradermally in the right deltoid region.
Altogether 101 of these preterm infants (26-37 weeks' gestation) returned to the neonatal clinic between two and four months after vaccination. Infants were excluded from the study only if they had severe congenital anomalies. The site of the vaccination was evaluated and graded as follows: no scar, or a papule of 1-2 mm, 3-4 mm, 4-5 mm, or >5 mm. The tuberculin purified protein derivative (PPD) test was then performed on the middle third of the flexor surface of the forearm. The PPD was purified lyophilised tuberculin from the Institute Merieux, Lyon, France. The intradermal injection was performed by a single nurse with 0v 1 ml of the solution, which contained 10 IU of purified tuberculin. The maximum transverse diameter of induration was measured with a transparent plastic ruler 48-72 hours after the test. The PPD test was graded as follows: non-reactive (-,1 mm induration) or an induration of 2-5 mm, 6-9 mm, or ¢10 mm.
Results
Of the 101 preterm infants who returned to the hospital for evaluation of the vaccination site no scar was found in 32, a papule of 1-2 mm in five, 3-4mm in 16, 4-5 mm in 31, and >5 mm in 17 (table 1) . The range of scar was 1-18 mm (mean 3-2 mm).
All these infants were tuberculin PPD tested but only 70 returned for the test to be read. Of these 70 infants no BCG scar was found in 22 and a scar found in 48 on initial evaluation of the vaccination site. The PPD test was negative in 22 (3 1%) , an induration of 2-5 mm was found in 26 (37%), 6-9 mm in 16 (23%), and ¢a 10 mm in six (9%). The range of induration was 0-15 mm (mean 4-1 mm) (see fig 1) . [33] [34] [35] [36] weeks'. We did not exclude any babies because of respiratory distress syndrome, ventilatory support, jaundice, or apnoea; the only exclusions were for major congenital anomalies. The presence of a BCG scar has been used as one of the criteria to assess the coverage of vaccination. The absence of scar has been found to be between 3-25% in different studies in term infants.9 10 and less than 10% in preterm infants.5 In this study 32% of the infants had no BCG scar and there was a significant difference for tuberculin conversion between infants with and without a BCG scar. When we compared the numbers of those with a scar and the numbers of those with a reactive PPD test between the present study and our previous study in term infants,1 the full term infants had a significantly higher number of BCG scars and tuberculin conversion (table 3) . Although the size of the tuberculin reaction after vaccination is not generally thought to influence the degree of protection offered by BCG, the nonreactive tuberculin test should be tested by a higher concentration of PPD (100 IU). We did not observe any complications of the vaccine such as lymphadenopathy or sterile abscess in the preterm infants. This could be due to the low response of preterm infants to BCG vaccination.
Our study indicates that giving BCG vaccination to preterm infants at birth results in a relatively high percentage of infants with no BCG scar (32%) and a non-reactive tuberculin PPD test (31%). We did not exclude our sick infants from the study, as most preterm infants of less than 32 weeks' gestation need ventilatory assistance and antibiotics; this Table 1 Difference between groups: X2=2 8314, p=0-2428. 
